Drugs / SclerFIX-IP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06034262 | Oct 2024 → Jan 2026 overdue | osteoarthritis, hand | TBF Genie Tissulaire | Recruiting | No outcome recorded |
| Phase 2 | NCT06038331 | May 2024 → Dec 2026 expected | osteoarthritis, hand | TBF Genie Tissulaire | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SclerFIX-IP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06034262 ↗ |
| Modality | Other / unclassified | “Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of amniotic membrane of umbilical cord used as an interposition implant in the STT joint” NCT06038331 ↗ |